We report a female patient, who presented as a carcinoma of unknown primary site with multiple tumors in breast, lung, stomach, and ovary, was confirmed to be lung adenocarcinoma as primary cancer through detecting EML4-ALK rearrangement by the next generation sequencing (NGS). The patient was treated with crizotinib and resulted in significant regression of the primary and metastatic tumors, but resistance to crizotinib was developed 5 months after the treatment. Targeted therapy was, therefore, switched to alectinib, one of the second-generation of anaplastic lymphoma kinase (ALK) inhibitors, with excellent therapeutic response till November 16th, 2021. This study suggested that NGS be recommended to detect ALK rearrangement in the patients with carcinoma of unknown primary site, and that resistance to targeted therapy with ALK inhibitors should be considered for personalized precision medicine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.prp.2022.154105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The X-Linked Tumor Suppressor TSPX Regulates Genes Involved in the EGFR Signaling Pathway and Cell Viability to Suppress Lung Adenocarcinoma.
Genes (Basel)
January 2025
Division of Cell and Developmental Genetics, Department of Medicine, Veterans Affairs Medical Center, and the Institute for Human Genetics, University of California, San Francisco, CA 94121, USA.
TSPX is an X-linked tumor suppressor that was initially identified in non-small cell lung cancer (NSCLC) cell lines. However, its expression patterns and downstream mechanisms in NSCLC remain unclear. This study aims to investigate the functions of TSPX in NSCLC by identifying its potential downstream targets and their correlation with clinical outcomes.
View Article and Find Full Text PDFAtypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma.
Biomolecules
December 2024
Department of Translational Medicine, University of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy.
Prostate cancer (PCa) is a high-prevalence disease usually characterized by metastatic spread to the pelvic lymph nodes and bones and the development of visceral metastases only in the late stages of disease. Positron Emission Tomography (PET) plays a key role in the detection of PCa metastases. Several PET radiotracers are used in PCa patients according to the stage and pathological features of the disease, in particular Ga/F-prostate-specific membrane antigen (PSMA) ligands.
View Article and Find Full Text PDFLung Cancers Associated with Cystic Airspaces.
Cancers (Basel)
January 2025
Clinic of Radiology EOC, Istituto Imaging della Svizzera Italiana (IIMSI), Via Tesserete 46, 6900 Lugano, CH, Switzerland.
Lung cancer, the second most common malignancy in both men and women, poses a significant health burden. Early diagnosis remains pivotal in reducing lung cancer mortality. Given the escalating number of computed tomography (CT) examinations in both outpatient and inpatient settings, radiologists play a crucial role in identifying early-stage pulmonary cancers, particularly non-nodular cancers.
View Article and Find Full Text PDFTLR7: A Key Prognostic Biomarker and Immunotherapeutic Target in Lung Adenocarcinoma.
Biomedicines
January 2025
Department of Immunology, The Fourth Military Medical University, Xi'an 710032, China.
The tumor microenvironment (TME) plays a crucial role in the progression of lung adenocarcinoma (LUAD). However, understanding its dynamic immune and stromal modulation remains a complex challenge. We utilized the ESTIMATE algorithm to evaluate the immune and stromal components of the LUAD TME from the TCGA database.
View Article and Find Full Text PDFFirst Clinical Experience of Ga-FAPI PET/CT in Tertiary Cancer Center: Identifying Pearls and Pitfalls.
Diagnostics (Basel)
January 2025
Department of Diagnostic Radiology, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan.
Over the past four years, Ga-fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) has been established at a tertiary cancer care facility in Jordan. This retrospective study aims to explore tracer uptake metrics across various epithelial neoplasms, identify diagnostic pitfalls associated with Ga-FAPI PET/CT, and evaluate the influence of Ga-FAPI PET/CT staging results on changes in therapeutic intent compared to gold standard molecular imaging modalities. A total of 48 patients with biopsy-confirmed solid tumors underwent 77 Ga-FAPI PET/CT examinations for molecular imaging assessment, encompassing neoplasms originating from the gastrointestinal tract, head and neck, hepatobiliary system, pancreas, breast, and lung.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!